NASDAQ: JAGXJaguar Health Inc Stock
$3.49-0.34 (-8.88%)
Updated Jun 13, 2025
JAGX Price
$3.49
Fair Value Price
N/A
Market Cap
$3.55M
52 Week Low
$3.49
52 Week High
$110.75
P/E
-0.02x
P/B
1.99x
P/S
0.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.55M
Earnings
-$39.73M
Gross Margin
82.3%
Operating Margin
-347.7%
Profit Margin
-343.9%
Debt to Equity
27.02
Operating Cash Flow
-$30M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
JAGX Overview
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JAGX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JAGX
Ranked#216 of 464
Ranked#216 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important JAGX news, forecast changes, insider trades & much more!
JAGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JAGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JAGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JAGX is good value based on its book value relative to its share price (1.99x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
JAGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more JAGX due diligence checks available for Premium users.
Valuation
JAGX fair value
Fair Value of JAGX stock based on Discounted Cash Flow (DCF)
Price
$3.49
Fair Value
-$0.98
Undervalued by
455.18%
JAGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JAGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-108.97x
Market
31.36x
JAGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.99x
Industry
4.66x
JAGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JAGX's financial health
Profit margin
Revenue
$2.2M
Net Income
-$10.5M
Profit Margin
-472.6%
JAGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
JAGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$51.5M
Liabilities
$48.1M
Debt to equity
27.02
JAGX's short-term assets ($30.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JAGX's short-term assets ($30.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JAGX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
JAGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
$0.0
Financing
$5.0M
JAGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JAGX vs Biotech Stocks
Jaguar Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.